 |
 |
It seems to me that the size of the sample (I believe 1000) is meant to control for individual differences in disease progression. Can someone knowledgable abut study design comment? I'm with Scott in being weary of the same old same old. Kathleen 2009/10/3 mschild <[log in to unmask]> > The abstract seemed to me to make a solid > >> case for the 1 mg dosage maybe slowing the progresssion of PD. >> > > It all seems very hypothetical. Selegiline was also supposed to slow the > progression and so was ropinirole and others. > Later they could never prove it. How do you test a slowing of progression > in a disease where everyone seems to have a different evolution? > But if it works for some, why not use it > maryse > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: mailto: > [log in to unmask] > In the body of the message put: signoff parkinsn > ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn